|
시장보고서
상품코드
2055001
AAV 유전자 치료 시장 : 벡터 혈청형별, 치료 영역별, 표적 조직별, 적응증별, 유전자 페이로드별, 개발 단계별, 제조 방법별, 최종사용자별, 지역별AAV Gene Therapy Market, By Vector Serotype, By Therapeutic Area, By Target Tissue, By Indication Type, By Gene Payload Type, By Development Stage, By Manufacturing Type, By End User, By Geography |
||||||
AAV 유전자 치료 시장은 2026년에 43억 5,000만 달러로 추정되며, 2033년까지 215억 7,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 25.7%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 43억 5,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 25.70% | 2033년 시장 규모 예측 : | 215억 7,000만 달러 |
세계 AAV 유전자 치료 시장은 현대 의학의 혁신적인 개척 분야로, 아데노연관바이러스(AAV) 벡터를 첨단 전달 시스템으로 활용하여 치료용 유전자를 표적 세포에 직접 전달함으로써 다양한 유전성 질환 및 후천성 질환을 치료하고 있습니다.
AAV 유전자 치료는 뛰어난 안전성 프로파일, 최소한의 면역원성, 그리고 숙주 유전체에 통합되지 않으면서도 장기적인 유전자 발현을 실현할 수 있는 능력 덕분에 획기적인 치료법으로 부상해 왔습니다.
이 혁신적인 치료법은 AAV 벡터의 고유한 특성을 활용하고 있습니다. AAV 벡터는 자연계에 존재하는 비병원성 바이러스로, 복제 능력을 제거하기 위해 철저하게 변형되었음에도 불구하고 다양한 조직 유형에서 분열 세포와 비분열 세포 모두에 유전자를 도입하는 탁월한 능력을 보유하고 있습니다.
이 시장은 유전성 망막 질환, 혈우병, 척수성 근위축증 및 다양한 중추신경계 질환을 포함한 광범위한 치료 용도를 아우르며, 수많은 임상시험을 통해 유망한 효능이 입증되었습니다. 전 세계 규제 당국이 AAV 기반 유전자 치료제를 지속적으로 승인하고 제약사들이 연구 개발 노력을 강화함에 따라, 벡터 공학의 기술적 진보, 제조 공정의 개선, 그리고 치료 대상의 확대에 힘입어 시장은 전례 없는 성장을 이루고 있습니다. 이러한 모든 요소가 결합되어, AAV 유전자 치료는 그동안 치료가 어려웠던 유전성 질환에 대한 획기적인 해결책으로서의 입지를 굳혀가고 있습니다.
시장 역학
세계 AAV 유전자 치료 시장은 헬스케어 분야 전반의 견실한 성장을 뒷받침하는 몇 가지 강력한 촉진요인에 힘입어 성장하고 있습니다. 주요 성장 동력은 전 세계적으로 유전성 질환 및 희귀질환의 유병률이 증가하고 있는 데다, 기존에는 불치병으로 여겨졌던 질환에 대한 효과적인 치료법에 대한 절실한 미충족 수요가 결합되어, 혁신적인 AAV 기반 치료 솔루션에 대한 막대한 시장 수요를 창출하고 있습니다.
조직 특이성 향상 및 전사 효율 개선을 동반한 새로운 AAV 캡시드 개발 등, 벡터 공학 분야의 눈부신 기술적 진보로 인해 이러한 치료법의 치료적 잠재력과 임상적 적용 가능성은 획기적으로 확대되었습니다. 미국 FDA 및 EMA와 같은 규제 당국이 확립한 희귀질환 치료제의 신속 승인 절차와 희귀의약품 지정을 포함한 지원적 규제 체계는 AAV 유전자 치료제의 개발 기간과 시장 진입을 가속화하고 있습니다.
그러나 시장에는 뚜렷한 제약이 존재하며, 그 주된 원인은 AAV 벡터 제조에 수반되는 매우 높은 제조 비용에 있습니다. 이는 치료비 상승으로 이어져 환자의 접근성을 제한할 뿐만 아니라, 전 세계 의료 시스템에 보험 급여와 관련된 문제를 야기하고 있습니다.
또한, AAV 벡터에 대한 면역원성 반응이나 유전독성 위험과 같은 잠재적인 안전성 우려는 여전히 규제상의 장벽으로 작용하여, 제품 승인 및 시장 침투를 지연시킬 가능성이 있습니다. 이러한 과제가 있음에도 불구하고, 희귀 유전성 질환에 그치지 않고 심혈관 질환, 신경퇴행성 질환, 안과 질환 등 보다 일반적인 질환으로의 치료 용도 확장에 힘입어 시장에는 막대한 기회가 창출되고 있습니다. 또한, 부유 배양 시스템이나 새로운 정제법 등 신흥 제조 기술을 통해 제조 비용 절감과 확장성 향상이 기대되며, 이는 궁극적으로 시장의 접근성과 성장 가능성을 높이는 결과로 이어질 것입니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 시장 성장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 주요 지표(기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략)를 바탕으로 전 세계 AAV 유전자 치료 시장의 주요 기업들을 분석했습니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 보고서는 전 세계 AAV 유전자 치료 시장을 다루며, 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 AAV 유전자 치료 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 AAV 유전자 치료 시장 : 벡터 혈청형별, 2021년-2033년
제5장 세계의 AAV 유전자 치료 시장 : 치료 영역별, 2021년-2033년
제6장 세계의 AAV 유전자 치료 시장 : 표적 조직별, 2021년-2033년
제7장 세계의 AAV 유전자 치료 시장 : 투여 경로별, 2021년-2033년
제8장 세계의 AAV 유전자 치료 시장 : 적응증 유형별, 2021년-2033년
제9장 세계의 AAV 유전자 치료 시장 : 유전자 페이로드 유형별, 2021년-2033년
제10장 세계의 AAV 유전자 치료 시장 : 개발 단계별, 2021년-2033년
제11장 세계의 AAV 유전자 치료 시장 : 제조 유형별, 2021년-2033년
제12장 세계의 AAV 유전자 치료 시장 : 최종사용자별, 2021년-2033년
제13장 세계의 AAV 유전자 치료 시장 : 지역별, 2021년-2033년
제14장 경쟁 구도
제15장 애널리스트의 제안
제16장 참고 문헌 및 조사 방법
LSH 26.06.19AAV Gene Therapy Market is estimated to be valued at USD 4.35 Bn in 2026 and is expected to reach USD 21.57 Bn by 2033, growing at a compound annual growth rate (CAGR) of 25.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.35 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 25.70% | 2033 Value Projection: | USD 21.57 Bn |
The global AAV gene therapy market represents a revolutionary frontier in modern medicine, utilizing Adeno-Associated Virus (AAV) vectors as sophisticated delivery systems to transport therapeutic genes directly into target cells for treating various genetic disorders and acquired diseases.
AAV gene therapy has emerged as a groundbreaking therapeutic approach due to its exceptional safety profile, minimal immunogenicity, and ability to achieve long-lasting gene expression without integrating into the host genome.
This innovative treatment modality leverages the unique characteristics of AAV vectors, which are naturally occurring, non-pathogenic viruses that have been extensively engineered to remove their replicative capacity while retaining their remarkable ability to transduce both dividing and non-dividing cells across multiple tissue types.
The market encompasses a diverse range of therapeutic applications including inherited retinal diseases, hemophilia, spinal muscular atrophy, and various central nervous system disorders, with numerous clinical trials demonstrating promising efficacy outcomes. As regulatory agencies worldwide continue to approve AAV-based gene therapies and pharmaceutical companies intensify their research and development efforts, the market is experiencing unprecedented growth driven by technological advancements in vector engineering, improved manufacturing processes, and expanding therapeutic targets that collectively position AAV gene therapy as a transformative solution for previously untreatable genetic conditions.
Market Dynamics
The global AAV gene therapy market is propelled by several compelling drivers that collectively fuel its robust expansion across the healthcare landscape. The primary growth catalyst stems from the increasing prevalence of genetic disorders and rare diseases worldwide, coupled with the urgent unmet medical need for effective treatments in conditions previously deemed incurable, creating substantial market demand for innovative AAV-based therapeutic solutions.
Significant technological advancements in vector engineering, including the development of novel AAV capsids with enhanced tissue specificity and improved transduction efficiency, have dramatically expanded the therapeutic potential and clinical applicability of these treatments. Supportive regulatory frameworks established by agencies such as the U.S. FDA and EMA, including expedited approval pathways for rare disease treatments and orphan drug designations, have accelerated the development timeline and market entry for AAV gene therapies.
However, the market faces notable restraints primarily centered around the exceptionally high manufacturing costs associated with AAV vector production, which translates into substantial treatment expenses that limit patient accessibility and create reimbursement challenges for healthcare systems globally.
Additionally, potential safety concerns including immunogenic responses to AAV vectors and the risk of genotoxicity continue to pose regulatory hurdles that may delay product approvals and market penetration. Despite these challenges, the market presents tremendous opportunities driven by expanding therapeutic applications beyond rare genetic diseases into more prevalent conditions such as cardiovascular diseases, neurodegenerative disorders, and ophthalmologic conditions, while emerging manufacturing technologies including suspension cell culture systems and novel purification methods promise to reduce production costs and improve scalability, ultimately enhancing market accessibility and growth potential.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global AAV gene therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis (AveXis), Spark Therapeutics (Roche), BioMarin Pharmaceutical, Sarepta Therapeutics, uniQure, Regenxbio, Audentes Therapeutics (Astellas), Voyager Therapeutics, MeiraGTx, Asklepios BioPharmaceutical (AskBio - Bayer), Krystal Biotech, Genethon, BridgeBio Gene Therapy, Passage Bio, and Solid Biosciences
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global AAV gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global AAV gene therapy market
Market Segmentation
- Vector Serotype Insights (Revenue, USD Bn, 2021 - 2033)
- AAV9
- AAV2
- AAV5
- AAV8
- AAV1
- Engineered/Synthetic AAV Variants
- Therapeutic Area Insights (Revenue, USD Bn, 2021 - 2033)
- Neurological Disorders
- Ophthalmic Disorders
- Rare Genetic Disorders
- Hematological Disorders
- Muscular Disorders
- Metabolic Disorders
- Cardiovascular Disorders
- Oncology
- Others
- Target Tissue Insights (Revenue, USD Bn, 2021 - 2033)
- Central Nervous System
- Eye/Retina
- Liver
- Muscle
- Lung
- Heart
- Blood/Bone Marrow
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Intravenous
- Intrathecal
- Intracerebral
- Subretinal
- Intravitreal
- Intramuscular
- Intracardiac
- Indication Type Insights (Revenue, USD Bn, 2021 - 2033)
- Monogenic Disorders
- Polygenic Disorders
- Gene Payload Type Insights (Revenue, USD Bn, 2021 - 2033)
- Gene Replacement
- Gene Silencing
- Gene Augmentation
- Development Stage Insights (Revenue, USD Bn, 2021 - 2033)
- Preclinical
- Phase I
- Phase II
- Phase III
- Manufacturing Type Insights (Revenue, USD Bn, 2021 - 2033)
- In-house Manufacturing
- Contract Manufacturing (CDMO/CMO)
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Biopharmaceutical Companies
- Research Institutes and Academic Centers
- Hospitals and Specialty Clinics
- Others (CROs)
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis (AveXis)
- Spark Therapeutics (Roche)
- BioMarin Pharmaceutical
- Sarepta Therapeutics
- uniQure
- Regenxbio
- Audentes Therapeutics (Astellas)
- Voyager Therapeutics
- MeiraGTx
- Asklepios BioPharmaceutical (AskBio - Bayer)
- Krystal Biotech
- Genethon
- BridgeBio Gene Therapy
- Passage Bio
- Solid Biosciences
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global AAV Gene Therapy Market, By Vector Serotype
- Global AAV Gene Therapy Market, By Therapeutic Area
- Global AAV Gene Therapy Market, By Target Tissue
- Global AAV Gene Therapy Market, By Route of Administration
- Global AAV Gene Therapy Market, By Indication Type
- Global AAV Gene Therapy Market, By Gene Payload Type
- Global AAV Gene Therapy Market, By Development Stage
- Global AAV Gene Therapy Market, By Manufacturing Type
- Global AAV Gene Therapy Market, By End User
- Global AAV Gene Therapy Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global AAV Gene Therapy Market, By Vector Serotype, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- AAV9
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- AAV2
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- AAV5
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- AAV8
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- AAV1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Engineered/Synthetic AAV Variants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global AAV Gene Therapy Market, By Therapeutic Area, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ophthalmic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Rare Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hematological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Muscular Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Metabolic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cardiovascular Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global AAV Gene Therapy Market, By Target Tissue, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Central Nervous System
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Eye/Retina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Liver
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Muscle
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Lung
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Heart
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Blood/Bone Marrow
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global AAV Gene Therapy Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Intrathecal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Intracerebral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Subretinal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Intravitreal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Intracardiac
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global AAV Gene Therapy Market, By Indication Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Monogenic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Polygenic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global AAV Gene Therapy Market, By Gene Payload Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Gene Replacement
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Gene Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Gene Augmentation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global AAV Gene Therapy Market, By Development Stage, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Preclinical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Phase I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Phase II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Phase III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global AAV Gene Therapy Market, By Manufacturing Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- In-house Manufacturing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Contract Manufacturing (CDMO/CMO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
12. Global AAV Gene Therapy Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Biopharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Research Institutes and Academic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hospitals and Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
13. Global AAV Gene Therapy Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Vector Serotype, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Vector Serotype, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Vector Serotype, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Vector Serotype, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Vector Serotype, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Vector Serotype, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
14. Competitive Landscape
- Novartis (AveXis)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Spark Therapeutics (Roche)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BioMarin Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sarepta Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- uniQure
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regenxbio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Audentes Therapeutics (Astellas)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Voyager Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- MeiraGTx
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Asklepios BioPharmaceutical (AskBio - Bayer)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Krystal Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Genethon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BridgeBio Gene Therapy
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Passage Bio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Solid Biosciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
15. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
16. References and Research Methodology
- References
- Research Methodology
- About us
